Amneal Pharmaceuticals (AMRX) Current Assets (2017 - 2026)

Amneal Pharmaceuticals' Current Assets history runs 10 years deep, the most recent figure standing at $1.8 billion for Q1 2026.

• On a quarterly basis, Current Assets rose 19.03% year-over-year to $1.8 billion in Q1 2026; TTM through Mar 2026 was $1.8 billion, a 19.03% increase from a year earlier, with the FY2025 full-year figure at $1.9 billion, up 20.37% from the prior year.
• Current Assets fell to $1.8 billion in Q1 2026 per AMRX's latest filing, from $1.9 billion in the prior quarter.
• Across five years, Current Assets topped out at $1.9 billion in Q4 2025 and bottomed at $1.3 billion in Q1 2023.
• The 5-year median for Current Assets is $1.5 billion (2024), against an average of $1.5 billion.
• Across the five-year window, Current Assets fell 10.9% in 2022 and gained 21.49% in 2025, its largest moves.
• Year by year, Current Assets stood at $1.4 billion in 2022, then retreated by 2.41% to $1.4 billion in 2023, then grew by 15.24% to $1.6 billion in 2024, then advanced by 20.37% to $1.9 billion in 2025, then slipped by 5.93% to $1.8 billion in 2026.
• Per Business Quant, the three latest AMRX Current Assets figures stand at $1.8 billion (Q1 2026), $1.9 billion (Q4 2025), and $1.8 billion (Q3 2025).